Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s DiseaseNovember 15, 2018 7:00 AM AbbVie (ABBV) Presents Positive Phase 3 Data Showing Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at AAGLNovember 14, 2018 5:40 PM AbbVie (ABBV) Says MAVYRET Shows High Virologic Cure Rates in Treatment-Naïve Hepatitis C Patients with Compensated CirrhosisNovember 13, 2018 11:31 AM Walmart, Home Depot adopt health insurer tactic in drug copay battleNovember 13, 2018 7:32 AM